Anúncio
Anúncio

ARCT

ARCT logo

Arcturus Therapeutics Holdings Inc. Common Stock

6.78
USD
Patrocinado
+0.01
+0.16%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pré-Mercado

6.78

0.00
-0.07%

Relatórios de Lucros ARCT

Rácio de surpresa positiva

ARCT separação 25 de 39 últimas estimativas.

64%

Próximo Relatório

Data do Próximo Relatório
04 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$18.24M
/
-$0.68
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+6.32%
/
+38.78%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-19.90%
/
-38.74%

Arcturus Therapeutics Holdings Inc. Common Stock earnings per share and revenue

On 10 de nov. de 2025, ARCT reported earnings of -0.49 USD per share (EPS) for Q3 25, beating the estimate of -0.83 USD, resulting in a 41.65% surprise. Revenue reached 17.15 milhão, compared to an expected 21.62 milhão, with a -20.67% difference. The market reacted with a -1.25% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analistas forecast an EPS of -0.68 USD, with revenue projected to reach 18.24 milhão USD, implying an aumentar of 38.78% EPS, and aumentar of 6.32% in Revenue from the last quarter.
FAQ
For Q3 2025, Arcturus Therapeutics Holdings Inc. Common Stock reported EPS of -$0.49, beating estimates by 41.65%, and revenue of $17.15M, -20.67% below expectations.
The stock price moved down -1.25%, changed from $8.78 before the earnings release to $8.67 the day after.
The next earning report is scheduled for 04 de mar. de 2026.
Based on 13 analistas, Arcturus Therapeutics Holdings Inc. Common Stock is expected to report EPS of -$0.68 and revenue of $18.24M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio